4/8
04:02 pm
smmt
Summit Therapeutics (SMMT) is now covered by Citigroup Inc.. They set a "buy" rating on the stock.
Low
Report
Summit Therapeutics (SMMT) is now covered by Citigroup Inc.. They set a "buy" rating on the stock.
4/8
08:03 am
smmt
Summit Therapeutics (SMMT) is now covered by Stifel Nicolaus. They set a "buy" rating and a $45.00 price target on the stock.
Medium
Report
Summit Therapeutics (SMMT) is now covered by Stifel Nicolaus. They set a "buy" rating and a $45.00 price target on the stock.
4/8
08:03 am
smmt
Summit Therapeutics (SMMT) is now covered by Stifel Nicolaus. They set a "buy" rating and a $45.00 price target on the stock.
Medium
Report
Summit Therapeutics (SMMT) is now covered by Stifel Nicolaus. They set a "buy" rating and a $45.00 price target on the stock.
4/8
06:19 am
smmt
Rating for SMMT
Medium
Report
Rating for SMMT
4/7
04:15 pm
smmt
Summit Therapeutics initiated with a Buy at Stifel
Medium
Report
Summit Therapeutics initiated with a Buy at Stifel
3/16
08:31 am
smmt
Rating for SMMT
Low
Report
Rating for SMMT
3/16
08:31 am
smmt
Rating for SMMT
Low
Report
Rating for SMMT
3/16
05:14 am
smmt
Summit Therapeutics downgraded to Hold from Buy at Jefferies
Low
Report
Summit Therapeutics downgraded to Hold from Buy at Jefferies
3/16
05:14 am
smmt
Summit Therapeutics downgraded to Hold from Buy at Jefferies
Low
Report
Summit Therapeutics downgraded to Hold from Buy at Jefferies
2/24
07:01 am
smmt
Summit Therapeutics (NASDAQ:SMMT) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
Low
Report
Summit Therapeutics (NASDAQ:SMMT) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
2/2
08:05 am
smmt
Summit Therapeutics (NASDAQ:SMMT) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.
Low
Report
Summit Therapeutics (NASDAQ:SMMT) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.
1/30
08:02 am
smmt
Summit Therapeutics (NASDAQ:SMMT) had its "market outperform" rating reaffirmed by analysts at Citigroup Inc..
Medium
Report
Summit Therapeutics (NASDAQ:SMMT) had its "market outperform" rating reaffirmed by analysts at Citigroup Inc..
1/21
06:34 am
smmt
Crescent Biopharma initiated with a Buy at Guggenheim
Medium
Report
Crescent Biopharma initiated with a Buy at Guggenheim
1/21
06:34 am
smmt
Crescent Biopharma initiated with a Buy at Guggenheim
Medium
Report
Crescent Biopharma initiated with a Buy at Guggenheim